LONDON, April 3, 2018 /PRNewswire/ --
Maurizio Rolando, Michael E Stern, Margarita Calonge; European Ophthalmic Review, 2017;11(Suppl 2):2-6; http://www.touchophthalmology.com/articles/modern-perspectives-dry-eye-disease.
(Logo: http://mma.prnewswire.com/media/515766/Touch_Medical_Logo.jpg )
Published recently as a supplement to European Ophthalmic Review, the peer-reviewed journal from touchOPHTHALMOLOGY, Rolando et al, discuss dry eye disease (DED), a disease of the lacrimal functional unit, is a complex autoimmune-based chronic inflammatory condition that can have a significant negative impact on quality of life and the patient's ability to effectively carry out everyday activities. Further, DED may lead to contact lens intolerance, and may adversely affect refractive surgical outcomes and be associated with post-ocular surgery complications. The ocular surface system is in constant dynamic equilibrium; however, if damage is severe or too prolonged, repair mechanisms can fail, initiating a feedback loop of increasing inflammation known as the 'vicious cycle'. Stress to the ocular surface triggers the initial inflammatory events that lead to autoimmunity; autoantibodies may contribute to complement dependent ocular surface pathology. With an aging population and with lifestyles becoming increasingly dependent on screen technology, the burden of DED is likely to escalate in the future. There are multiple challenges in the management of DED, not least the lack of medications for chronic use.
The full article is open-access and available here:
http://www.touchophthalmology.com/articles/modern-perspectives-dry-eye-disease
Disclosure: Maurizio Rolando has the following potential conflicts of interest to report as consultant, speaker or research grant recipient: Alcon, Allergan, Bausch & Lomb, Eupharma, Farmigea, Horus, Medivis, Novartis, Pfizer, Santen, Sifi, Shire, SOOFT, Thea, TRB Chemedica. Michael E Stern has worked as a consultant for Allergan, Shire, Novaliq and an employee of ImmunEyez, LLC. Over the past 12 months, Margarita Calonge has had research contracts, consultantships, given lectures and been involved in advisory boards for the following: Allergan, Chiesi, Esteve, Ferrer International, Horus Pharma, Santen, Shire and Zealand Pharma. However, Margarita Calonge has no financial interest in any product or technology presented in this symposium. This article covers to proceedings of a symposium and has not been submitted to external peer reviewers but was reviewed by the editorial board for accuracy before publication. The publication of this article was supported an Independent Educational Grant from Shire. The views and opinions expressed in the article are those of the authors and not necessarily those of Shire.
touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the European Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
www.touchOPHTHALMOLOGY.com
"Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142".
For inquires please contact: Nicola Cartridge - Editorial Director [email protected] +44-(0)-207-193-3186
"Leading the Debate on the Advances in Healthcare"
SOURCE touchOPHTHALMOLOGY
Advertisement
Maurizio Rolando, Michael E Stern, Margarita Calonge; European Ophthalmic Review, 2017;11(Suppl 2):2-6; http://www.touchophthalmology.com/articles/modern-perspectives-dry-eye-disease.
Advertisement
(Logo: http://mma.prnewswire.com/media/515766/Touch_Medical_Logo.jpg )
Published recently as a supplement to European Ophthalmic Review, the peer-reviewed journal from touchOPHTHALMOLOGY, Rolando et al, discuss dry eye disease (DED), a disease of the lacrimal functional unit, is a complex autoimmune-based chronic inflammatory condition that can have a significant negative impact on quality of life and the patient's ability to effectively carry out everyday activities. Further, DED may lead to contact lens intolerance, and may adversely affect refractive surgical outcomes and be associated with post-ocular surgery complications. The ocular surface system is in constant dynamic equilibrium; however, if damage is severe or too prolonged, repair mechanisms can fail, initiating a feedback loop of increasing inflammation known as the 'vicious cycle'. Stress to the ocular surface triggers the initial inflammatory events that lead to autoimmunity; autoantibodies may contribute to complement dependent ocular surface pathology. With an aging population and with lifestyles becoming increasingly dependent on screen technology, the burden of DED is likely to escalate in the future. There are multiple challenges in the management of DED, not least the lack of medications for chronic use.
The full article is open-access and available here:
http://www.touchophthalmology.com/articles/modern-perspectives-dry-eye-disease
Disclosure: Maurizio Rolando has the following potential conflicts of interest to report as consultant, speaker or research grant recipient: Alcon, Allergan, Bausch & Lomb, Eupharma, Farmigea, Horus, Medivis, Novartis, Pfizer, Santen, Sifi, Shire, SOOFT, Thea, TRB Chemedica. Michael E Stern has worked as a consultant for Allergan, Shire, Novaliq and an employee of ImmunEyez, LLC. Over the past 12 months, Margarita Calonge has had research contracts, consultantships, given lectures and been involved in advisory boards for the following: Allergan, Chiesi, Esteve, Ferrer International, Horus Pharma, Santen, Shire and Zealand Pharma. However, Margarita Calonge has no financial interest in any product or technology presented in this symposium. This article covers to proceedings of a symposium and has not been submitted to external peer reviewers but was reviewed by the editorial board for accuracy before publication. The publication of this article was supported an Independent Educational Grant from Shire. The views and opinions expressed in the article are those of the authors and not necessarily those of Shire.
touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the European Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
www.touchOPHTHALMOLOGY.com
"Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142".
For inquires please contact: Nicola Cartridge - Editorial Director [email protected] +44-(0)-207-193-3186
"Leading the Debate on the Advances in Healthcare"
SOURCE touchOPHTHALMOLOGY
